GlassScriptPhysician profile
Erica Witek
NPI 1801487095
$4,021.58
in general payments reported to CMS, 2019-2025
43 companies · $62.86 in 2025
The $62.86 reported for 2025 was less than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $904 · 2022: $2,056 · 2023: $547 · 2024: $452 · 2025: $62.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $763 · Long Term Medical Supply Or Device Loan: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $762.99 |
| Long Term Medical Supply Or Device Loan | $299.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $561.36 | 2022-2023 | |
| Axonics, INC. | $327.44 | 2024 | Axonics |
| Astrazeneca Pharmaceuticals LP | $251.17 | 2021-2023 | Lynparza |
| Seagen INC. | $219.50 | 2022 | |
| Redhill Biopharma INC. | $207.22 | 2021-2022 | |
| Novo Nordisk INC | $140.58 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $136.98 | 2022 | |
| Abbvie INC. | $135.69 | 2022-2024 | |
| Medtronic, INC. | $133.88 | 2023 | Interstim |
| Lilly USA, LLC | $122.03 | 2021-2022 | |
| Amgen INC. | $119.29 | 2022-2023 | Kyprolis |
| Foundation Medicine, INC. | $107.94 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.67 | 2021 | |
| Exelixis INC. | $104.72 | 2022 | |
| G1 Therapeutics, INC. | $100.04 | 2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Witek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.